Dihydromyricetin attenuates age-related macular degeneration: pharmacological effects and exploration of putative targets.

ABSTRACT:

Introduction

Age-related macular degeneration (AMD) is a leading cause of vision loss in older adults, with limited effective treatments available. This study aimed to investigate the pharmacological effects of dihydromyricetin (DHM) on AMD and to identify its putative pharmacological targets through network analysis and molecular docking approaches.

Methods

In vitro experiments established an AMD model using sodium iodate (SI)-induced ARPE-19 cells, with CCK-8 assays determining 15 mM SI as the optimal modeling concentration and 100 μM DHM as the optimal treatment concentration. For in vivo validation, an AMD model was generated in C57 mice via tail vein injection of SI (30 mg/kg). Subsequent oral gavage with DHM (50 or 100 mg/kg) was administered. Integrated

SUBMITTER: Zhou H 

PROVIDER: S-EPMC12408514 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature